Skip to main content

CORRECTION article

Front. Pharmacol., 29 September 2023
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: Cucurbitacin-B instigates intrinsic apoptosis and modulates Notch signaling in androgen-dependent prostate cancer LNCaP cells

  • 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha’il, Ha’il, Saudi Arabia
  • 2Department of Pharmaceutics, College of Pharmacy, University of Ha’il, Ha’il, Saudi Arabia
  • 3Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
  • 4Department of Clinical Pharmacy, College of Pharmacy, University of Ha’il, Ha’il, Saudi Arabia

A Corrigendum on
Cucurbitacin-B instigates intrinsic apoptosis and modulates Notch signaling in androgen-dependent prostate cancer LNCaP cells

by Alafnan A, Khalifa NE, Hussain T and Osman ME (2023). Front. Pharmacol. 14:1206981. doi: 10.3389/fphar.2023.1206981

In the published article, there was an error in the Funding statement. The correct Funding statement appears below.

“This research has been funded by Deputy for Research and Innovation, Ministry of Education through Initiative of Institutional Funding at University of Ha’il—Saudi Arabia through project number IFP-22 112”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: anti-cancer, apoptosis, cell cycle, cucurbitacin-B, Notch signaling

Citation: Alafnan A, Khalifa NE, Hussain T and Osman ME (2023) Corrigendum: Cucurbitacin-B instigates intrinsic apoptosis and modulates Notch signaling in androgen-dependent prostate cancer LNCaP cells. Front. Pharmacol. 14:1286507. doi: 10.3389/fphar.2023.1286507

Received: 31 August 2023; Accepted: 21 September 2023;
Published: 29 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Alafnan, Khalifa, Hussain and Osman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ahmed Alafnan, a.alafnan@uoh.edu.sa

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.